Synchron, the startup behind an FDA breakthrough neuroprosthesis device that aims to give patients with paralysis the ability to control digital devices with their thoughts, has been cleared by the FDA to begin a clinical trial with human participants.
Called the COMMAND trial, the study will take place later this year at Mount Sinai Hospital in New York and will include six patients with severe...
